Since then, it has become increasingly clear that ALK is a prevalent oncogene that is aberrantly expressed in a variety of tumors, including some B-cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT), some non-small-cell lung cancers (NSCLC), renal carcinoma (RCC), colorectal carcinoma (CRC) and neuroblastoma (NB) [4–6]. Here, ALK is linked to non-small cell lung carcinoma.